Overview

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin
Sofosbuvir